



# SUVEN Life Sciences

**Communication to investors**

**Sep 2013**

11-Nov-13

*2013-14 Q2 results*



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



# FINANCIAL QUICK VIEW

		Q2 Sep 13	HY Sep 13
Growth in revenue		201.49%	118.03%
Growth in PAT		601.92%	421.15%
Growth in EBIDTA		550.40%	373.52%
Growth in Pre-R&D EBIDTA		401.67%	255.03%
Increase in R&D Costs		162.13%	65.89%
R&D to sales		11.81%	9.81%


# MAJOR PROFITABILITY RATIOS



	Q2 Sep 13	HY Sep 13
PAT to Income	30.06%	28.60%
EBIDTA to Income	47.20%	44.70%
Cash Flow to Income	31.52%	30.24%
Pre-R&D EBITDA to Income	59.02%	54.51%



# INCOME COMPARISON




11-Nov-13

2013-14 Q2 results




# PROFIT COMPARISON





# EBIDTA COMPARISON




11-Nov-13

2013-14 Q2 results




# R & D – EXPENDITURE





# PRE-R&D EBIDTA




11-Nov-13

2013-14 Q2 results



# PRE-R&D CASHFLOW



11-Nov-13

2013-14 Q2 results



# Status for the half year

- Suven has **607** product patents for **18** inventions and **35** process patents
- Number of active CRAMS projects during period - **90**
- SUVN 502 entered Phase **1b** clinical trial in USA
- Suven Life Sciences presenting the positive pharmacology data of 4 NCEs at Society for Neuroscience (SFN-2013) Annual Meeting held at San Diego, USA between Nov 9 and 14.